These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants. Curtiss FR; Fairman KA J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846 [No Abstract] [Full Text] [Related]
5. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Resch B; Gusenleitner W; Nuijten MJ; Lebmeier M; Wittenberg W Clin Ther; 2008 Apr; 30(4):749-60. PubMed ID: 18498923 [TBL] [Abstract][Full Text] [Related]
8. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Wang D; Bayliss S; Meads C Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564 [TBL] [Abstract][Full Text] [Related]
10. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660 [TBL] [Abstract][Full Text] [Related]
11. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623 [TBL] [Abstract][Full Text] [Related]
20. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. Lee SR; Kwok KL; Ng DKK; Hon KL J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]